Albany Cancer Center - Patroon Creek office has reopened. Use lower lot entrance for all appointments.
Albany Medical Center patients should continue to use upper lot entrance to check in for appointments in Suite 210.
Radiation, PET and CT patients use radiation entrance in lower lot. Learn More

Clinical Trials & Research

Ph 3 BYL719 + nabpax TNBC PIK3CA

EPIK-B3: A phase III, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation (CBYL719H12301)

Disease Types: Breast,&nbs

Available at: {clinical_trial_location backspace="7"}Ph 3 BYL719 + nabpax TNBC PIK3CA, {/clinical_trial_location}

Principal Investigator: {clinical_trial_principle_investi} , {/clinical_trial_principle_investi}

{clinical_trial_description}